From Antidepressant Tianeptine to Street Drug ZaZa: A Narrative Review

Tianeptine is often incorrectly described as a selective serotonin reuptake inhibitor, but it actually is a µ-opioid receptor agonist with anxiolytic effects. It has been approved since the last 1980s in about 24 countries as a treatment for depression, but it was never cleared to market in the United States for this purpose. Nevertheless, tianeptine joined the billion-dollar US market of nootropics as ZaZa or Tianna Red and is widely available online and in small shops without a prescription, to the point that it has been nicknamed “gas station heroin.” While the therapeutic dose range is about 25 to 50 mg/day, tianeptine abusers may take 100 times that amount. Tolerance occurs rapidly and users who seek to recapture the short-lived euphoric effects of the drug have to take more and more. Social media has peer-support sites for those trying to discontinue tianeptine. Tianeptine is associated with multiple side effects at high doses along with dependence, withdrawal symptoms, toxicity, respiratory depression, and even mortality. Agitation is more often a presenting symptom of withdrawal than toxicity. Tianeptine is often used by polysubstance drug abusers who may be unaware of the drug’s dangers. Few clinicians are aware of tianeptine and most urine assays do not screen for it. Greater awareness is needed for this drug and steps must be taken as tianeptine or “gas station heroin” is emerging as a new public health threat.

[1]  R. Sullivan,et al.  Microdose Induction of Buprenorphine in a Patient Using Tianeptine. , 2022, Journal of addiction medicine.

[2]  W. Dewey,et al.  Opioid-like adverse effects of tianeptine in male rats and mice , 2022, Psychopharmacology.

[3]  D. Epstein,et al.  When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use , 2021, The American journal of drug and alcohol abuse.

[4]  M. Kurz,et al.  Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health , 2020, Clinical toxicology.

[5]  A. Karim,et al.  Tianeptine Abuse Leading to an Episode of Psychosis: A Case Report and Literature Review , 2020, Journal of psychiatric practice.

[6]  K. Aalto,et al.  Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial , 2019, Pediatric Rheumatology.

[7]  A. Walley,et al.  Use of Buprenorphine-Naloxone in the Treatment of Tianeptine Use Disorder. , 2019, Journal of addiction medicine.

[8]  Alan Hsu,et al.  Tianeptine Abuse and Dependence: Case Report and Literature Review. , 2018, Psychosomatics.

[9]  E. Bakota,et al.  Case Reports of Fatalities Involving Tianeptine in the United States. , 2018, Journal of analytical toxicology.

[10]  R. Law,et al.  Characteristics of Tianeptine Exposures Reported to the National Poison Data System — United States, 2000–2017 , 2018, MMWR. Morbidity and mortality weekly report.

[11]  R. Hoffman,et al.  Poison control center experience with tianeptine: an unregulated pharmaceutical product with potential for abuse , 2018, Clinical toxicology.

[12]  W. Cubała,et al.  Tianeptine Abuse and Dependence in Psychiatric Patients: A Review of 18 Case Reports in the Literature , 2018, Journal of psychoactive drugs.

[13]  Jordan Sloshower,et al.  Online Sales of Unscheduled Pharmaceutical Agents: A Case Report of Tianeptine Use in the United States , 2017, Journal of addiction medicine.

[14]  C. Wolf,et al.  Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine. , 2017, Journal of analytical toxicology.

[15]  R. Hen,et al.  The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor , 2017, Neuropsychopharmacology.

[16]  R. Jardri,et al.  Neonatal Abstinence Syndrome Following Tianeptine Dependence During Pregnancy , 2016, Pediatrics.

[17]  K. Chinthapalli The billion dollar business of being smart , 2015, BMJ : British Medical Journal.

[18]  Bo-Hyung Kim,et al.  Pharmacokinetic and bioequivalence assessment of two formulations of tianeptine sodium in healthy male volunteers. , 2014, International journal of clinical pharmacology and therapeutics.

[19]  Oğuzhan Koyuncu,et al.  Risk Management in Tianeptine Abuse in Turkey: A National Experience , 2013 .

[20]  A. Şen,et al.  The role of cultural interaction in Tianeptine Abuse and Different Tianeptine Application Methods. , 2013, Turkish journal of anaesthesiology and reanimation.

[21]  J. Micallef,et al.  Assessment of abuse of tianeptine from a reimbursement database using ‘doctor‐shopping’ as an indicator , 2012, Fundamental & clinical pharmacology.

[22]  M. Duru,et al.  Amitriptyline and tianeptine poisoning treated by naloxone , 2010, Human & experimental toxicology.

[23]  K. Gambashidze,et al.  Addictive potential of Tianeptine - the threatening reality. , 2009, Georgian medical news.

[24]  T. Jay,et al.  The neurobiological properties of Tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation , 2009, Molecular Psychiatry.

[25]  T. Uzbay Tianeptine: Potential influences on neuroplasticity and novel pharmacological effects , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[26]  D. Vieira,et al.  Fatal intoxication with tianeptine (Stablon). , 2007, Forensic science international.

[27]  C. Kısa,et al.  Is it possible to be dependent to Tianeptine, an antidepressant? A case report , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[28]  R. Le Boisselier,et al.  [Misuse of tianeptine: five cases of abuse]. , 2003, Annales de medecine interne.

[29]  P. Vandel,et al.  [Abuse of tianeptine. A case report]. , 1999, L'Encephale.

[30]  F. López-Muñoz,et al.  Tianeptine, an atypical pharmacological approach to depression. , 2019, Revista de psiquiatria y salud mental.

[31]  G. Koob,et al.  The neurobiology of addiction. , 2003, Journal of neural transmission. Supplementum.

[32]  C. Spencer,et al.  Tianeptine , 2001, CNS drugs.

[33]  G. Koob,et al.  The Neurobiology of Addiction , 1997, Alcohol health and research world.

[34]  P. Benfield,et al.  Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. , 1995, Drugs.

[35]  J. Guelfi,et al.  Clinical safety and efficacy of tianeptine in 1,858 depressed patients treated in general practice. , 1992, Neuropsychobiology.

[36]  H. Ashton Protracted withdrawal syndromes from benzodiazepines. , 1991, Journal of substance abuse treatment.